Wie hoch ist der Preis für Orexo AB (publ) (ORXOF)

Preis für Orexo AB (publ) (ORXOF) ist $1.55

Wie hoch ist die Marktkapitalisierung für Orexo AB (publ) (ORXOF)

Marktkapitalisierung für Orexo AB (publ) (ORXOF) ist $54.45M

Orexo AB (publ) (ORXOF) KBV

Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia. Looking to its future offerings, Orexo is actively progressing several developmental candidates: OX124, an emergency medication for naloxone rescue; OX125, an intervention for nalmefene rescue; OX640, a potential treatment for allergic reactions; and OX338, a sublingual ketorolac tablet designed for moderate to severe pain relief. Furthermore, the company is engaged in the OX-MPI program, which aims to tackle microvascular diseases often linked with chronic inflammatory conditions. Beyond traditional drugs, Orexo provides a selection of digital health therapies, such as deprexis, a program tailored for treating mild to severe depression; vorvida, targeted at alcohol use disorder; and modia, a digital tool for managing opioid use disorder. Established in 1994, Orexo AB (publ) operates from its primary corporate offices located in Uppsala, Sweden.

Jahr	P/B-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/B-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5.5207	-	IN

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land